hydrochlorothiazide has been researched along with Insulin Resistance in 23 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 9.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 9.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients." | 9.13 | Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "5 mg of hydrochlorothiazide on glucose metabolism insulin sensitivity and lipids was evaluated in hypertensive non-insulin-dependent diabetes." | 9.08 | The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1995) |
| " Nondiabetics with hypertension (N=30) were started on (or changed to) hydrochlorothiazide (HCTZ) 12." | 7.73 | Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. ( Falkner, B; Francos, G; Kushner, H, 2006) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 6.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus." | 5.20 | Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. ( D'Angelo, A; Dario Ragonesi, P; Derosa, G; Franzetti, I; Maffioli, P; Querci, F, 2015) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 5.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "To compare the effect of delapril/manidipine vs olmesartan/hydrochlorothiazide (HCTZ) combination on insulin sensitivity and plasma fibrinogen in obese hypertensive patients." | 5.13 | Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| " Since these metabolic defects are accentuated by obesity, we thought it important to compare the effects of 3 months' treatment with either lisinopril (20 mg/day) or low dose hydrochlorothiazide (12." | 5.08 | Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. ( Chen, YD; Clinkingbeard, C; Foote, J; Hollenbeck, CB; Jeppesen, J; Maheux, P; Pei, D; Reaven, GM, 1995) |
| "5 mg of hydrochlorothiazide on glucose metabolism insulin sensitivity and lipids was evaluated in hypertensive non-insulin-dependent diabetes." | 5.08 | The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1995) |
| "In short-term studies (4 to 6 months) we have reported that antihypertensive treatment with beta-adrenergic blockade and thiazide diuretics induced insulin resistance, hyperinsulinemia, and a deranged lipid profile; the ACE inhibitor captopril increased insulin sensitivity without affecting serum lipids." | 5.07 | Long-term metabolic effects of antihypertensive drugs. ( Berne, C; Lind, L; Lithell, H; Pollare, T, 1994) |
| " Potassium supplementation improves their insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and ameliorates hypertension, hypertriglyceridemia, hyperglycemia, and insulin resistance." | 3.74 | Thiazide diuretics exacerbate fructose-induced metabolic syndrome. ( Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007) |
| "Hydrochlorothiazide (HCTZ) is used to manage hypertension and heart failure; however, its side effects include mild hypokalemia, metabolic abnormalities, and volume depletion, which might have deleterious effects on renal and endothelial function." | 3.74 | Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. ( Byer, K; Croker, BP; Hu, H; Johnson, RJ; Mu, W; Nakagawa, T; Patel, JM; Reungjui, S; Roncal, CA; Simoni, J; Sitprija, V; Srinivas, T; Wesson, D, 2007) |
| " Nondiabetics with hypertension (N=30) were started on (or changed to) hydrochlorothiazide (HCTZ) 12." | 3.73 | Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. ( Falkner, B; Francos, G; Kushner, H, 2006) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 2.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "Insulin resistance is associated with a number of risk factors for atherosclerosis, including glucose intolerance, hypertension, and dyslipidemia." | 2.38 | Insulin resistance. An often unrecognized problem accompanying chronic medical disorders. ( Bell, DS, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Derosa, G | 2 |
| Querci, F | 1 |
| Franzetti, I | 1 |
| Dario Ragonesi, P | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Cicero, AF | 1 |
| Tocci, G | 1 |
| Miura, S | 1 |
| Saku, K | 1 |
| Eriksson, JW | 1 |
| Jansson, PA | 1 |
| Carlberg, B | 1 |
| Hägg, A | 1 |
| Kurland, L | 1 |
| Svensson, MK | 1 |
| Ahlström, H | 1 |
| Ström, C | 1 |
| Lönn, L | 1 |
| Ojbrandt, K | 1 |
| Johansson, L | 1 |
| Lind, L | 2 |
| Martinez-Martin, FJ | 1 |
| Rodriguez-Rosas, H | 1 |
| Peiro-Martinez, I | 1 |
| Soriano-Perera, P | 1 |
| Pedrianes-Martin, P | 1 |
| Comi-Diaz, C | 1 |
| Guo, Q | 1 |
| Mori, T | 1 |
| Jiang, Y | 1 |
| Hu, C | 1 |
| Ohsaki, Y | 1 |
| Yoneki, Y | 1 |
| Nakamichi, T | 1 |
| Ogawa, S | 1 |
| Sato, H | 1 |
| Ito, S | 1 |
| Prior, SJ | 1 |
| Brown, NJ | 1 |
| Kumar, S | 1 |
| Painter, CA | 1 |
| Vaughan, DE | 1 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Dell'Oro, R | 1 |
| Trevano, FQ | 1 |
| Bombelli, M | 1 |
| Scopelliti, F | 1 |
| Facchini, A | 1 |
| Mancia, G | 1 |
| Rinder, MR | 1 |
| Spina, RJ | 1 |
| Peterson, LR | 1 |
| Koenig, CJ | 1 |
| Florence, CR | 1 |
| Ehsani, AA | 1 |
| Falkner, B | 1 |
| Francos, G | 1 |
| Kushner, H | 1 |
| Reungjui, S | 2 |
| Roncal, CA | 2 |
| Mu, W | 2 |
| Srinivas, TR | 1 |
| Sirivongs, D | 1 |
| Johnson, RJ | 2 |
| Nakagawa, T | 2 |
| Hu, H | 1 |
| Croker, BP | 1 |
| Patel, JM | 1 |
| Srinivas, T | 1 |
| Byer, K | 1 |
| Simoni, J | 1 |
| Wesson, D | 1 |
| Sitprija, V | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Corradi, L | 1 |
| Preti, P | 1 |
| Mugellini, A | 1 |
| Bakris, G | 1 |
| Molitch, M | 1 |
| Zhou, Q | 1 |
| Sarafidis, P | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Sowers, JR | 1 |
| Tkacheva, ON | 1 |
| Shumbutova, AIu | 1 |
| Novikova, IM | 1 |
| Samsonenko, NS | 1 |
| Guseva, KIu | 1 |
| Reaven, GM | 1 |
| Clinkingbeard, C | 1 |
| Jeppesen, J | 1 |
| Maheux, P | 1 |
| Pei, D | 1 |
| Foote, J | 1 |
| Hollenbeck, CB | 1 |
| Chen, YD | 1 |
| Shamiss, A | 1 |
| Carroll, J | 1 |
| Peleg, E | 1 |
| Grossman, E | 1 |
| Rosenthal, T | 1 |
| Pollare, T | 1 |
| Berne, C | 1 |
| Lithell, H | 1 |
| Bell, DS | 1 |
| Zhao, D | 1 |
| Klauser, R | 1 |
| Prager, R | 1 |
| Gaube, S | 1 |
| Gisinger, C | 1 |
| Schnack, C | 1 |
| Küenburg, E | 1 |
| Schernthaner, G | 1 |
| Senft, G | 1 |
| Schwarzbach, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
1 review available for hydrochlorothiazide and Insulin Resistance
| Article | Year |
|---|---|
Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.
Topics: Acanthosis Nigricans; Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteri | 1993 |
12 trials available for hydrochlorothiazide and Insulin Resistance
| Article | Year |
|---|---|
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Topics: Adipokines; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2015 |
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Compo | 2008 |
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; C | 2011 |
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2003 |
Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults.
Topics: Aged; Angiotensins; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Compo | 2004 |
Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2008 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.
Topics: Administration, Oral; Blood Glucose; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hydroc | 1995 |
The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Enalapril; Female; Glycated Hemo | 1995 |
Long-term metabolic effects of antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Glucose; Captopril; Cholesterol, H | 1994 |
Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucos | 1991 |
10 other studies available for hydrochlorothiazide and Insulin Resistance
| Article | Year |
|---|---|
Metabolic approaches to antihypertensive treatment in diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium | 2015 |
Angiotensin II type 1 receptor blocker combined with hydrochlorothiazide for the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dose-Response Relationship, Drug; | 2008 |
Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Fructose; Glucose Clamp Technique; Hy | 2012 |
Anti-hypertensive therapy and insulin sensitivity: regulation through the microcirculation?
Topics: Animals; Capillaries; Fructose; Hydrochlorothiazide; Insulin Resistance; Losartan; Male; Muscle, Ske | 2012 |
Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cholesterol; Cholesterol, LDL; Female; Glucose | 2006 |
Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Topics: Allopurinol; Animals; Blood Pressure; Body Weight; Diuretics; Fructose; Gout Suppressants; Hydrochlo | 2007 |
Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Diuretics; Hydrochlorothiazide; Hypertension, Ren | 2007 |
[Clinical assessment of metabolic effects of antihypertensive therapy].
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Gl | 2008 |
[A preliminary study of insulin resistance in essential hypertension, simple obesity and acromegaly].
Topics: Acromegaly; Adult; Blood Glucose; Captopril; Drug Therapy, Combination; Female; Humans; Hydrochlorot | 1993 |
["Therapy with saluretics and insulin resistance in diabetes mellitus"].
Topics: Diabetes Mellitus; Diabetic Coma; Diuretics; Humans; Hydrochlorothiazide; Insulin; Insulin Resistanc | 1967 |